Review Article

The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature

Table 2

Effect of tulsi on immune system and viral infections in human clinical trials.

Clinical
domain
Authors
(year)
Study designJadad
score
Participants (age range)Tulsi
extract
InterventionComparatorOutcome
measure(s)
Adverse
events (s)
DurationDosage

ImmunomodulationVenu Prasad (2014) [76]Randomized,
placebo-controlled
clinical trial
330 healthy
adults
(18–30 years)
Ethanolic
tulsi leaves
in Bar
2 weeks1 bar × 2/day
(1000 mg tulsi)
Not described
“control bar”
↑physical performance
↓fatigue and CK levels
less increase in lactic acid
None
Mondal et al. (2011) [77]Randomized,
double-blind,
placebo-controlled
cross-over
522 healthy
adults
(22–37 years)
Ethanolic
tulsi leaves
4 weeks
(+3 weeks wash out)
300 mg/dayCellulose
300 mg/day
Increased cytokine level,
interferon-ϒ,  & interleukin-4
None
Sharma (1983) [78]Open clinical trial120 adults,
asthma
Aqueous
tulsi leaves
tablets
1 week500 mg × 3/dayNoneRelief within 3 days,
improved vital capacity
None

Viral infectionsRajalakshmi et al. (1986) [79]Clinical trial020 cases,
viral hepatitis
(10–60 years)
Aqueous
extract fresh
tulsi leaves
2 weeks for
mild cases
3 weeks for
Severe cases
10 g dailyNoneSymptoms all improved
within 2 weeks
None
Das et al. (1983) [80]Randomized
clinical trial
parallel-controlled
114 adults,
viral
encephalitis
Aqueous
extract fresh
tulsi leaves
4 weeks2.5 g
4 times/day
12 mg/day
dexamethasone
treated group
Increased survival rate
compared to steroid
Not
reported

CK = creatine kinase; TPE = tropical pulmonary eosinophilia.
Intervention duration included wash-out periods where applicable until study was completed.
Participants include both control and intervention groups completing the study and excluded any drop-outs.
Same results as previously published (Mondal et al., 2010).
Tulsi enriched bar: each 25 g bar contained oats, resin, peanuts, skimmed milk powder, sugar, and honey and 0.5% ethanolic tulsi.